| | | | | | | | | | | | | | | | |
| | Number of Shares Beneficially Owned | | | Percent of Shares Beneficially Owned
(%) | |
Name of Beneficial Owner | | Before Offering | | | After Offering | | | Before Offering | | | After Offering | |
5% or Greater Stockholders: | | | | | | | | | | | | | | | | |
Entities affiliated with Decheng Capital Global Life Sciences Fund IV, L.P.(1) | | | 22,602,700 | | | | | | | | 17.2 | % | | | | |
Entities affiliated with Vickers Venture Fund VI Pte. Ltd.(2) | | | 22,519,148 | | | | | | | | 17.1 | % | | | | |
Jane Wu Lee, M.D.(3) | | | 25,102,249 | | | | | | | | 19.1 | % | | | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | | | | |
Tien-Li Lee, M.D.(4) | | | 25,102,249 | | | | | | | | 19.1 | % | | | | |
Bryan Jones, Ph.D.(5) | | | 701,041 | | | | | | | | * | | | | | |
Manasi Jaiman, M.D., M.P.H. | | | — | | | | | | | | — | | | | | |
Jeffrey Chi, Ph.D.(6) | | | 18,509,483 | | | | | | | | 14.1 | % | | | | |
Roy D. Baynes, M.D., Ph.D. | | | — | | | | | | | | — | | | | | |
Susan E. Graf | | | — | | | | | | | | — | | | | | |
Victor Tong, Jr. | | | — | | | | | | | | — | | | | | |
All executive officers and directors as a group (8 persons)(7) | | | 48,080,452 | | | | | | | | 36.4 | % | | | | |
* Represents beneficial ownership of less than 1%.
(1) Consists of (i) 19,777,363 shares of our common stock issuable upon conversion of shares of Series C convertible preferred stock held by Decheng Capital Global Life Sciences Fund IV, L.P. (Fund IV), and (ii) 2,825,337 shares of our common stock issuable upon conversion of shares of Series C convertible preferred stock held by Decheng Capital Global Healthcare Fund (Master), LP (Healthcare Fund). Decheng Capital Management IV (Cayman), LLC (GP IV) is the general partner of Fund IV and Dr. Xiangmin Cui is the sole manager of GP IV. Fund IV, GP IV and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Fund IV. Decheng Capital Global Healthcare GP, LLC (Healthcare GP) is the general partner of Healthcare Fund and Dr. Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Healthcare Fund, Healthcare GP and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Healthcare Fund. The address of Fund IV and Healthcare Fund is c/o Decheng Capital, 3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025.
(2) Consists of (i) 1,130,135 shares of our common stock issuable upon conversion of shares of Series C convertible preferred stock held by Vickers Venture Co-investment LLC (Vickers Co-investment), (ii) 2,100,010 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held by Vickers Venture Global Deep-tech Fund I L.P. (Vickers Deep-tech), (iii) 13,875,429 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held by Vickers Venture Fund VI Pte. Ltd. (Vickers Fund VI), (iv) 3,503,919 shares of our common stock issuable upon conversion of shares of Series B convertible preferred stock held by Vickers Fund VI, (v) 1,524,642 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held by held by Vickers Venture Fund VI (Plan) Pte. Ltd. (Vickers Fund VI Plan), and (vi) 385,013 shares of our common stock issuable upon conversion of shares of Series B convertible preferred stock held by held by Vickers Fund VI Plan. Vickers Co-investment is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Vickers Deep-tech is managed by its general partner Vickers Venture Partners VI (CI) Ltd, which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise sole voting and dispositive power over the securities held by Vickers Deep-tech. The sole shareholder of Vickers Fund VI Plan is Vickers Venture Global Deep-tech Fund II (Plan) L.P., which is in turn managed by its general partner Vickers Venture Partners VI (CI) Ltd. Vickers Venture Partners VI (CI) Ltd is managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise sole voting and dispositive power over the securities held by Vickers Fund VI Plan. The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.À.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. The address of Vickers Co-investment and Vickers Deep-tech is Willow House, Cricket Square, PO Box 709, Grand Cayman KY1-1107, Cayman Islands. The address of Vickers Fund VI and Vickers Fund VI Plan is 1 Harbourfront Avenue, #16-06, Keppel Bay Tower Singapore 098632.
(3) Consists of (i) 12,490,919 shares of our common stock held directly, (ii) 12,188,412 shares of our common stock held directly held by Dr. Lee’s spouse, Tien-Li Lee, M.D., our Chief Executive Officer, (iii) 350,002 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held by Tien-Li Lee, M.D., and (iv) 72,916 shares of our common stock subject to options held by Tien-Li Lee, M.D., that are exercisable within 60 days of December 1, 2024.
(4) Consists of (i) 12,188,412 shares of our common stock held directly, (ii) 350,002 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held directly, (iii) 12,490,919 shares of our common stock held directly by Dr. Lee’s spouse, Jane Wu Lee, M.D., and (iv) 72,916 shares of our common stock subject to options that are exercisable within 60 days of December 1, 2024.
(5) Consists solely of shares of our common stock subject to options that are exercisable within 60 days of December 1, 2024, of which 150,000 shares would be unvested and subject to a right of repurchase in our favor to the extent such options were exercised.
(6) Consists of (i) 1,130,135 shares of our common stock issuable upon conversion of shares of Series C convertible preferred stock held by Vickers Co-investment, (ii) 13,875,429 shares of our common stock issuable upon conversion of shares of Series A convertible preferred stock held by Vickers Fund VI, and (iii) 3,503,919 shares of our common stock issuable upon conversion of shares of Series B convertible preferred stock held by Vickers Fund VI. Vickers Co-investment is managed by Vickers Venture Partners (S) Pte. Ltd., which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. The sole shareholders of Vickers Fund VI are Vickers
200